刘仍允
研究员，博士生导师
研究方向：甲状腺癌；肿瘤遗传与表观遗传
电子邮件： liury9@mail.sysu.edu.cn
个人简介

中山大学附属第一医院研究员，博士生导师，国家优秀青年科学基金获得者，广东特支计划青年拔尖人才。2012年在苏州大学取得博士学位，2013年起在约翰霍普金斯大学接受博士后训练，2019年7月经中山大学百人计划引进回国，在中山一院精准医学研究院工作至今。

Dr. Rengyun Liu is a principal investigator (PI) in the Institute of Precision Medicine, The First Affiliated Hospital of Sun Yat-sen University (FAH-SYSU) in Guangzhou, China. Dr. Liu obtained his Ph.D. from Soochow University in 2012, then entered the postdoctoral program at the Johns Hopkins University School of Medicine and received the “Young Investigator Award” in 2018. Dr. Liu joined FAH-SYSU in 2019.

团队介绍

课题组主要从事甲状腺癌精准诊疗的分子基础和转化应用研究，旨在通过鉴定和解析甲状腺癌发生发展过程中的基因突变、DNA甲基化和组蛋白修饰异常，揭示甲状腺癌的基因组特征和发病机理，为临床诊断、患者危险分级和靶向治疗提供理论依据。

Our group primarily focuses on the genomic signature of thyroid cancer and its clinical implications. We analyze genetic variants, DNA methylation, and aberrant histone modifications to uncover the genomic drivers of the disease and translate these findings into actionable clinical tools. Our ultimate objective is to establish a rigorous scientific basis for improving diagnostic accuracy, refining patient risk stratification, and identifying novel vulnerabilities for personalized targeted therapies.

代表性成果
  1. Zhu L#, Jiang K#, Huang J, Zhang Q, Chen Y, Hu G, Lin B, Lv W, Feng P*, Liu R*. DNA Hypermethylation Suppresses Thyroid Peroxidase Expression and May be a Promising Diagnostic Marker for Thyroid Cancer. Thyroid. 2026; DOI: 10.1177/10507256261427034.
  2. Chen M#, Jiang K#, Zhang Q, Xiao X, Zhu L, Sang Y, Hu G, Yu S, Hong S, Lv W, Xiao H*, Liu R*. DDX21 Links BRAF V600E and TERT to Promote Thyroid Cancer Progression. Thyroid. 2026; DOI: 10.1177/10507256261417697.
  3. Hu G, Xue J, Yu J, Dou Q, Sang Y, Han A, Lv W, Li J*, Liu R*. High Prevalence of TBC1D12 5′UTR Mutations in Anaplastic Thyroid Cancer. Thyroid. 2025; 35(1): 115-119.
  4. Li S, Hu G, Chen Y, Sang Y, Tang Q, Liu R. TERT upstream promoter methylation regulates TERT expression and acts as a therapeutic target in TERT promoter mutation-negative thyroid cancer. Cancer Cell Int. 2024; 24(1): 271.
  5. Chen Y#, Sang Y#, Li S, Xue J, Chen M, Hong S, Lv W, Sehgal K, Xiao H*, Liu R*. The ERK inhibitor GDC-0994 selectively inhibits growth of BRAF mutant cancer cells. Transl Oncol. 2024; 45: 101991.
  6. Xiao X#, Chen M#, Sang Y, Xue J, Jiang K, Chen Y, Zhang L, Yu S, Lv W, Li Y, Liu R*, Xiao H*. Methylation-Mediated Silencing of ATF3 Promotes Thyroid Cancer Progression by Regulating Prognostic Genes in the MAPK and PI3K/AKT Pathways. Thyroid. 2023; 33(12): 1441-1454.
  7. Liu R, Zhu G, Tan J, Shen X, Xing M. Genetic trio of BRAF and TERT alterations and rs2853669TT in papillary thyroid cancer aggressiveness. JNCI. 2024; 116(5): 694-701.
  8. Liu R, Tan J, Shen X, Jiang K, Wang C, Zhu G, Xing M. Therapeutic targeting of FOS in mutant TERT cancers through removing TERT suppression of apoptosis via regulating survivin and TRAIL-R2. PNAS. 2021; 118(11): e2022779118.
  9. Liu R, Zhang T, Zhu G, Xing M. Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer. Nat Commun. 2018; 9(1): 579.
  10. Liu R#, Bishop J#, Zhu G, Zhang T, Ladenson PW, Xing M. Mortality risk stratification by combining BRAF V600E and TERT promoter mutations in papillary thyroid cancer: genetic duet of BRAF and TERT promoter mutations in thyroid cancer mortality. JAMA Oncol. 2017; 3(2): 202-208.
招生招聘

招收基础医学(分子医学专业)硕士/博士研究生；

招聘博士后和研究助理(长期有效)，博士后年薪30-36万，研究助理年薪12-15万。欢迎对科研有浓厚兴趣、踏实认真、有集体责任心的青年学者加入。